Principal Investigator

Matthew Smith

Cancer Signalling and Structural Biology

Subscribe to the newsletter

After obtaining his Ph.D. in Molecular and Medical Genetics at the University of Toronto, Dr. Matthew Smith carried out a postdoctoral fellowship in the Medical Biophysics Department of the Ontario Cancer Institute.

He joined IRIC in December of 2015 as a Principal Investigator in the Cancer Signalling and Structural Biology Research Unit. He holds a position of Research Associate Professor in the Department of Pathology and Cell Biology at the Université de Montréal’s Faculty of Medicine, and a Tier II Canada Research Chair in Cancer Signalling and Structural Biology.

Principal Investigator, Cancer Signalling and Structural Biology Research Unit, IRIC

Associate Professor, Department of Pathology and Cell Biology, Université de Montréal

Cancer Signalling and Structural Biology Research Unit

Marcelle-Coutu Pavilion, 4306-11

Phone (office)
(514) 343-5704
Fax
(514) 343-7780
Email
matthew.james.smith@umontreal.ca
Apply for a M.Sc. or a Ph.D.

Cancer Signalling and Structural Biology

The research carried out by Matthew J. Smith and his team aims to integrate modern experimental approaches in structural biology, biophysics, evolutionary bioinformatics and cell biology to help identify and understand both normal and disrupted cell signalling at a mechanistic and systems level.

Discover the research unit View the research team

Research topics

Publications

  • July 15, 2024

    Complex interplay between RAS GTPases and RASSF effectors regulates subcellular localization of YAP.

    Singh S, Bernal Astrain G, Hincapie AM, Goudreault M, Smith M
    EMBO Rep 2024-07-15 ;

  • April 12, 2024

    Mapping the global interactome of the ARF family reveals spatial organization in cellular signaling pathways.

    Quirion L, Robert A, Boulais J, Huang S, Astrain GB, Strakhova R, Jo CH, Kherdjemil Y, Faubert D, Thibault MP, Kmita M, Baskin JM, Gingras AC, Smith M, Côté JF
    J Cell Sci 2024-04-12 ;

  • January 1, 2024

    Profiling Complex RAS-Effector Interactions Using NMR Spectroscopy.

    Strakhova R, Smith M
    Methods Mol Biol 2024-01-01 ;2797:195-209

  • September 20, 2023

    CBFA2T3::GLIS2 Pediatric Acute Megakaryoblastic Leukemia is Sensitive to BCL-XL Inhibition by Navitoclax and DT2216.

    Gress V, Roussy M, Boulianne L, Bilodeau M, Cardin S, El-Hachem N, Lisi V, Khakipoor B, Rouette A, Farah A, Théret L, Aubert L, Fatima F, Audemard E, Thibault P, Bonneil E, Chagraoui J, Laramée L, Gendron P, Jouan L, Jammali S, Paré B, Simpson SM, Tran TH, Duval M, Teira P, Bittencourt H, Santiago R, Barabé F, Sauvageau G, Smith M, Hébert J, Roux PP, Gruber TA, Lavallée VP, Wilhelm B, Cellot S
    Blood Adv 2023-09-20 ;

  • See all publications

Awards and distinctions

  • Tier 2 Canada Research Chair in Cancer Signalling and Structural Biology, 2016